Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Covid drug effective in treating FIP, study finds
Without treatment, many cats with FIP quickly deteriorate.
The human drug may result in a high survival rate.

An anti-viral drug used to treat humans with Covid-19 has proved highly effective in treating cats with feline infectious peritonitis (FIP).

Remdesivir, which was made available to prescribe by veterinary surgeons in 2021, could now form part of a tailored treatment plan, shortening the length of FIP treatment.

FIP is caused by a mutated feline coronavirus. The disease can cause a build-up of fluid, extreme muscle and weight loss, and can ultimately result in organ failure.

Without a proper treatment plan, many cats with FIP will deteriorate with little chance of survival.

Researchers from the Royal (Dick) School of Veterinary Studies assessed data from its Hospital for Small Animals, which frequently treats cats with FIP. While using a treatment plan including Remdesivir, the hospital reported a survival rate of over 85 per cent among its patients.

One of the first cats to be treated with with the drug was Rebus, a ten-year-old domestic short-haired cat.

Rebus was referred to the the hospital's Feline Service after showing rapid weight and muscle loss. He was not eating, was lethargic, and was drinking and urinating excessively.

An examination revealed that he was critically anaemic, had enlarged lymph nodes and recorded a high white blood cell count. He required fluids and pain relief and the nursing team had to help him eat.

A needle biopsy of Rebus' lymph notes confirmed the illness was FIP. He was also found to be suffering from kidney damage.

Rebus originally received injections of Remdesivir, before being moved on to its active ingredient, GS-441524.

Within three months, he made a full recovery from FIP. Three years later, Rebus continues to live an active life and is receiving ongoing care for chronic kidney disease.

Although usually harmless in the gut, feline FIP can become dangerous if it mutates and migrates into immune cells. An estimated 40-50 per cent of cats carry the virus, reaching 80-100 per cent of cats in a multi-cat household.

Clinicians are now developing a patient-centred treatment plan designed to reduce drug resistance and make treatment easier.

Conor O'Halloran, resident in internal medicine, said: “I remember when FIP was a death sentence. The advent of these medications to be able to provide safe and legal treatment has been revolutionary for us as cat-loving vets.”

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.